US 3299067A
· Regnier et al.
· 1967
[cited by applicant]
US 3457263A
· Regnier et al.
· 1969
[cited by applicant]
US 3485757A
· Shapiro et al.
· 1969
[cited by applicant]
US 3489757A
· Koppe et al.
· 1970
[cited by applicant]
US 4600025A
· Grigg et al.
· 1986
[cited by applicant]
US 5935974A
· Rae et al.
· 1999
[cited by applicant]
US 7582769B2
· Murray et al.
· 2009
[cited by applicant]
US 7666875B2
· Gallagher, Jr. et al.
· 2010
[cited by applicant]
US 8008326B2
· Borza et al.
· 2011
[cited by applicant]
US 8952166B2
· Ding et al.
· 2015
[cited by applicant]
US 9120781B2
· Li et al.
· 2015
[cited by applicant]
US 20070027328A1
· Aronhime et al.
· 2007
[cited by applicant]
US 20080300276A1
· Borza et al.
· 2008
[cited by applicant]
US 20100022517A1
· Richards et al.
· 2010
[cited by applicant]
US 20110053982A1
· Fay et al.
· 2011
[cited by applicant]
US 20110060012A1
· Meyers et al.
· 2011
[cited by applicant]
US 20220143042A1
· Quattropani et al.
· 2022
[cited by applicant]
US 20240285615A1
· Beher et al.
· 2024
[cited by applicant]
US 20250115604A1
· Quattropani et al.
· 2025
[cited by applicant]
CN 103435606A
· 2013
[cited by applicant]
EP 2301936A1
· 2011
[cited by applicant]
EP 2687507A1
· 2014
[cited by applicant]
FR 1311316A
· 1962
[cited by applicant]
GB 1061247A
· 1967
[cited by applicant]
JP 2010270034A
· 2010
[cited by applicant]
JP 2012514605A
· 2012
[cited by applicant]
JP 2013512252A
· 2013
[cited by applicant]
RU 2251548C2
· 2005
[cited by applicant]
WO WO9321181A1
· 1993
[cited by applicant]
WO WO9743279A1
· 1997
[cited by applicant]
WO WO9846590A1
· 1998
[cited by applicant]
WO WO9921850A1
· 1999
[cited by applicant]
WO WO02094799A2
· 2002
[cited by applicant]
WO WO03092678A1
· 2003
[cited by applicant]
WO WO2004002481A1
· 2004
[cited by applicant]
WO WO2004005293A2
· 2004
[cited by applicant]
WO WO2004022558A2
· 2004
[cited by applicant]
WO WO2004094380A1
· 2004
[cited by applicant]
WO WO2005110982A2
· 2005
[cited by applicant]
WO WO2006092049A1
· 2006
[cited by applicant]
WO WO2007008541A2
· 2007
[cited by applicant]
WO WO2007115077A2
· 2007
[cited by applicant]
WO WO2007135398A1
· 2007
[cited by applicant]
WO WO2007146122A2
· 2007
[cited by applicant]
WO WO2008012623A1
· 2008
[cited by applicant]
WO WO2008025170A1
· 2008
[cited by applicant]
WO WO2009011904A1
· 2009
[cited by applicant]
WO WO2009053373A1
· 2009
[cited by applicant]
WO WO2009131926A1
· 2009
[cited by applicant]
WO WO2010018868A1
· 2010
[cited by applicant]
WO WO2010021381A1
· 2010
[cited by applicant]
WO WO2010022517A1
· 2010
[cited by applicant]
WO WO2010026989A1
· 2010
[cited by applicant]
WO WO2010080874A1
· 2010
[cited by applicant]
WO WO2010089127A1
· 2010
[cited by applicant]
WO WO2010101949A1
· 2010
[cited by applicant]
WO WO2010108115A1
· 2010
[cited by applicant]
WO WO2010108268A1
· 2010
[cited by applicant]
WO WO2010151318A1
· 2010
[cited by applicant]
WO WO2011066352A1
· 2011
[cited by applicant]
WO WO2011140640A1
· 2011
[cited by applicant]
WO WO2012037298A1
· 2012
[cited by applicant]
WO WO2012061927A1
· 2012
[cited by applicant]
WO WO2012062157A1
· 2012
[cited by applicant]
WO WO2012062759A1
· 2012
[cited by applicant]
WO WO2012083435A1
· 2012
[cited by applicant]
WO WO2012117219A1
· 2012
[cited by applicant]
WO WO2013028715A1
· 2013
[cited by applicant]
WO WO2013066729A1
· 2013
[cited by applicant]
WO WO2014023723A1
· 2014
[cited by applicant]
WO WO2014032187A1
· 2014
[cited by applicant]
WO WO2014159234A1
· 2014
[cited by applicant]
WO WO2015083028A1
· 2015
[cited by applicant]
WO WO2015128333A1
· 2015
[cited by applicant]
WO WO2015164508A1
· 2015
[cited by applicant]
WO WO2016030443
· 2016
[cited by examiner]
WO WO2016030443A1
· 2016
[cited by applicant]
WO WO2017001660A1
· 2017
[cited by applicant]
WO WO2017076900A1
· 2017
[cited by applicant]
WO WO2017087858A1
· 2017
[cited by applicant]
WO WO2017087863A1
· 2017
[cited by applicant]
WO WO2017091818A1
· 2017
[cited by applicant]
WO WO2017106254A1
· 2017
[cited by applicant]
WO WO2017144633A1
· 2017
[cited by applicant]
WO WO2017144635A1
· 2017
[cited by applicant]
WO WO2017144639A1
· 2017
[cited by applicant]
WO WO2017223243A1
· 2017
[cited by applicant]
WO WO2018026371A1
· 2018
[cited by applicant]
WO WO2018109198A1
· 2018
[cited by applicant]
WO WO2018109202A1
· 2018
[cited by applicant]
WO WO2018140299A1
· 2018
[cited by applicant]
WO WO2018141984A1
· 2018
[cited by applicant]
WO WO2018153507A1
· 2018
[cited by applicant]
WO WO2018153508A2
· 2018
[cited by applicant]
WO WO2018154133A1
· 2018
[cited by applicant]
WO WO2018217558A1
· 2018
[cited by applicant]
Abdel-Magid, A. F. et al. “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures”, J. Org. Chem., 1996, 61, 3849-3862.
[cited by applicant]
Aitipamula, S. et al. “Polymorphs, Salts, and Cocrystals: What's in a Name?”, Cryst. Growth Des., 2012, 12(5), 2147-2152.
[cited by applicant]
Albertson, N. F. “Alkylation with Non-ketonic Mannich Bases. Aminothiazoles and Pyrrole”, J. Am. Chem. Soc., 1948, 70(2), 669-670.
[cited by applicant]
Andres, J. I. et al. “Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging”, J. Med…
[cited by applicant]
Ansari, S. A. et al. “The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration”, Front. Neurosci., 2019, 13, Article 473, 9 pages.
[cited by applicant]
Apsunde, T. D. et al. “Microwave-Assisted Iridium-Catalyzed Synthesis of Nicotine and Anabasine Derivatives”, Synthesis, 2013, 45(15), 2120-2124.
[cited by applicant]
Aube, J. et al. “Intramolecular Schmidt reaction of alkyl azides”, J. Am. Chem. Soc. 1991, 113(23), 8965-8966.
[cited by applicant]
Augustine, J. K. et al. “Propylphosphonic anhydride (T3P®): an efficient reagent for the one-pot synthesis of 1,2,4-oxadiazoles, 1,3,4-oxadiazoles, and 1,3,4-thiadiazoles”, Tetrahedron, 2009, 65, 9989-9996.
[cited by applicant]
Bastin, R. J. et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, Org. Proc. Res. Dev., 2000, 4(5), 427-435.
[cited by applicant]
Berge, S. M. et al. “Pharmaceutical Salts”, J. Pharm. Sci., 1977, 1-19.
[cited by applicant]
Biscoe, M. R. et al. “A New Class of Easily Activated Palladium Precatalysts for Facile C-N Cross-Coupling Reactions and Low Temperature Oxidative Addition of Aryl Chlorides”, J. Am. Chem. Soc., 2008, 130, 6686-6687.
[cited by applicant]
Bohnert, T. et al. “Plasma Protein Binding: From Discovery to Development”, J. Pharm. Sci., 2013, 102, 2953-2994.
[cited by applicant]
Bras, N. F. et al. “Glycosidase inhibitors: a patent review (2008-2013)”, Expert Opin. Ther. Pat., 2014, 24(8), 857-874.
[cited by applicant]
Bundgaard, H. “Design and Application of Pro-drugs”, A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, 1991, Chapter 5, 113-191.
[cited by applicant]
Bundgaard, H. “Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities”, Design of Prodrugs, 1985, 1 page.
[cited by applicant]
Calcagno, A. M. “Comparison of Drug Transporter Levels in Normal Colon, Colon Cancer, and Caco-2 Cells: Impact on Drug Disposition and Discovery”, Mol. Pharm., 2006, 3(1), 87-93.
[cited by applicant]
CAS Registry (Online) Nos. 948053-91-6; 540512-02-5; 697229-62-2; 346662-52-0; 345992-64-5 (STN database summary sheets) Sep. 26, 2007, 16 pages.
[cited by applicant]
“Chemical Encyclopedia”, vol. 4, pp. 990-993, 1988. (Machine translation attached).
[cited by applicant]
Chen, W. “Redox-Neutral α-Arylation of Amines”, Org. Lett., 2014, 16(3), 2014, 730-732.
[cited by applicant]
Chen, Y. et al. “Discovery of new acetylcholinesterase and butyrylcholinesterase inhibitors through structure-based virtual screening”, RSC Adv., 2017, 7(6), 3429-3438.
[cited by applicant]
Chrovian, C. C. et al “A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Ca…
[cited by applicant]
Collet, A. “Resolution of Racemates: Did you say ‘Classical?’”, Angew. Chem. Int. Ed., 1998, 37(23), 3239-3241.
[cited by applicant]
Dai, W. et al. “Highly Chemoselective and Enantioselective Catalytic Oxidation of Heteroaromatic Sulfides via High-Valent Manganese(IV)-Oxo Cation Radical Oxidizing Intermediates”, ACS Catal., 2017, 7, 4890-4895.
[cited by applicant]
Damasio, A. R. “Alzheimer's Disease And Related Dementias”, Cecil Textbook of Medicine, 20th Edition, vol. 2, 1996, 1992-1996.
[cited by applicant]
Dassanayaka, S. et al. “O—GlcNAc and the cardiovascular system”, Pharmacol. Ther., 2014, 142, 62-71.
[cited by applicant]
Database PubChem Compound, NCBI; Apr. 9, 2016; XP002768133, Database accession No. CID 118902929, 10 pages.
[cited by applicant]
Database Pubchem Compound (Online) NCBI; Jan. 24, 2012, XP002768130, Database accession No. CID 54914491, 11 pages.
[cited by applicant]
Database PubChem Compound (Online) NCBI; May 28, 2009; XP002768131, Database accession No. CID 28798635, 9 pages.
[cited by applicant]
Database Registry, Chemical Abstracts Service, Jan. 11, 2017, XP002768132, Database accession No. 2055841-81-9, 4 pages.
[cited by applicant]
Database Registry, Chemical Abstracts Service, 2016, CID120907609, 10 pages.
[cited by applicant]
Database Registry (online) Chemical abstract service, Columbus, Ohio, US; Dec. 6, 2011, “Piperazine, 1-[1-(1,3-benzodioxol-5-yl)ethyl]-4-(5-bromo-6-methoxy-2-pyridinyl)-”, Database accession No. 1349611-60-4, 1 page.
[cited by applicant]
Dorfmueller, H. C. et al. “Cell-Penetrant, Nanomolar O—GlcNAcase Inhibitors Selective against Lysosomal Hexosaminidases”, Chem. Biol., 2010, 17, 1250-1255.
[cited by applicant]
Dubois, B. et al. “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria”, Lancet Neurol., 2014, 13, 614-629.
[cited by applicant]
Dubois, B. et al. “Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria”, Alzheimers Dement., 2016, 12, 292-323.
[cited by applicant]
Dyatkin, A.B. et al. “Determination of the Absolute Configuration of a Key Tricyclic Component of a Novel Vasopressin Receptor Antagonist by Use of Vibrational Circular Dichroism”, Chirality, 2002, 14, 215-219.
[cited by applicant]
Ellman, J. A. et al. “N-tert-Butanesulfinyl !mines: Versatile Intermediates for the Asymmetric Synthesis of Amines”, Acc. Chem. Res., 2002, 35, 984-995.
[cited by applicant]
Fleury-Bregeot, N. et al. “Suzuki-Miyaura Cross-Coupling of Potassium Alkoxyethyltri-fluoroborates: Access to Aryl/Heteroarylethyloxy Motifs”, J. Org. Chem. 2012, 77(22), 10399-10408.
[cited by applicant]
Fors, B. P. et al. “A Highly Active Catalyst for Pd-Catalyzed Amination Reactions: Cross-Coupling Reactions Using Aryl Mesylates and the Highly Selective Monoarylation of Primary Amines Using Aryl Chlorides”, J. Am. Che…
[cited by applicant]
Frehel, D. et al. “New synthesis of 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine”, J. Heterocycl. Chem., 1985, 22, 1011-1016.
[cited by applicant]
Frings, M. et al. “Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery”, Eur. J. Med. Chem., 2017, 126, 225-245.
[cited by applicant]
Goho, A. “Tricky Business”, Science News, 2004, 166(8), 122-124.
[cited by applicant]
Golub, T. R. et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring”, Science, 1999, 286, 531-537.
[cited by applicant]
Gong, C. X. et al. “O—GlcNAcylation: A regulator of tau pathology and neurodegeneration”, Alzheimers Dement., 2016, 12, 1078-1089.
[cited by applicant]
Gould, P. L. “Salt selection for basic drugs”, Int. J. Pharm., 1986, 33, 201-217.
[cited by applicant]
Graham, D. L. et al. “Increased O—GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy”, Neuropharmacology, 2014, 79, 307-313.
[cited by applicant]
Gujjar, R. et al. “Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice”, J. Med. Chem., 2011, 54(11), …
[cited by applicant]
Gura et al. “Systems for Identifying New Drugs are Often Faulty”, Science, 1997, 278,1041-1042.
[cited by applicant]
Haleblian, J. “Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications”, J. Pharm. Sci., 1975, 64(8), 1269-1288.
[cited by applicant]
Haleblian, J. et al.“Pharmaceutical Applications of Polymorphism”, J. Pharm. Sci., 1969, 58(8), 911-929.
[cited by applicant]
Hemming, K. “Product Class 6: 1,2,4-Oxadizoles”, Sci. Synth., 2004, 13(6), 127-184.
[cited by applicant]
Yamanaka, H. et al. Chemical Abstract, “Separation of Optical Isomers”, Japan, Gakkai Shopping Santa, 1989, 21 pages.
[cited by applicant]
Hulikal, V. “Deuterium Labeled Compounds in Drug Discovery Process”, Abstract, Bioorganics and Applied Materials Pvt Ltd., 2010, 1 page.
[cited by applicant]
Jakopin, Z. et al. “Recent Advances in the Synthesis of 1,2,4- and 1,3,4-Oxadiazoles”, Curr. Org. Chem., 2008, 12(10), 850-898.
[cited by applicant]
Johnson, J. J. et al. “Relationships Between Drug Activity in NCI Preclinical in vitro and in vivo Models and Early Clinical Trials”, Brit. J. Cancer., 2001, 84, 1424-1431.
[cited by applicant]
Kempson, J. “Name Reactions in Heterocyclic Chemistry II”, John Wiley & Sons. Eds. Jie Jack Li and E. J. Corey, 2011, 299-308.
[cited by applicant]
Kim, E. J. “Chemical Arsenal for the Study of O—GlcNAc”, Molecules, 2011, 16, 1987-2022.
[cited by applicant]
Kim, E. J. et al. “Enzymatic characterization of O—GlcNAcase isoforms using a fluorogenic GlcNAc substrate”, Carbohydrate Research, 2006, 341(8), 971-982.
[cited by applicant]
Kim, Y. et al. “Discovery of β-Arrestin Biased Ligands of 5-HT7R”, J. Med. Chem. 2018, 61, 7218-7233.
[cited by applicant]
Knapp, S. et al. “An Allosamizoline/ Glucosamine Hybrid NAGase Inhibitor”, Synlett, 1997, 5, 435-436.
[cited by applicant]
Layzer, R. B. “Degenerative Diseases Of The Nervous System”, Cecil Textbook of Medicine, 20th Edition, vol. 2, 1996, 2050-2057.
[cited by applicant]
Lefebvre, T. “Recall sugars, forget Alzheimer's”, Nat. Chem. Bio., 2012, 8(4), 325-326.
[cited by applicant]
Legros, J. et al. “Applications of Catalytic Asymmetric Sulfide Oxidations to the Syntheses of Biologically Active Sulfoxides”, Adv. Synth. Catal., 2005, 347, 19-31.
[cited by applicant]
Liu, X. et al. “Rational Use of Plasma Protein and Tissue Binding Data in Drug Design”, J. Med. Chem., 2014, 57, 8238-8248.
[cited by applicant]
Mariappa, D. et al. “A mutant O—GlcNAcase as a probe to reveal global dynamics of the
[cited by applicant]
Marotta, N. P. et al., “O—GlcNAc modification blocks the aggregation and toxicity of the Parkinson's disease associated protein α-synuclein”, Nat. Chem., 2015, 7(11), 913-920.
[cited by applicant]
Marwaha, A. et al. “Bioisosteric Transformations and Permutations in the Triazolopyrimidine Scaffold To Identify the Minimum Pharmacophore Required for Inhibitory Activity against Plasmodium falciparum Dihydroorotate De…
[cited by applicant]
Masuda, N. et al. “Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides”, Bioorg. Med. Chem., 2004, 12, 6171-6182.
[cited by applicant]
Merchant, R. R. et al. “Regioselective Preparation of Saturated Spirocyclic and Ring-Expanded Fused Pyrazoles”, J. Org. Chem., 2014, 79(18), 8800-8811.
[cited by applicant]
Micksch, M. et al. “Synthesis of 1,2-Diaryl- and 1-Aryl-2-alkylimidazoles with Sterically Demanding Substituents”, Eur. J. Org. Chem. 2013, 27, 6137-6145.
[cited by applicant]
Miller III, B. R. et al. “Design of e-pharmacophore models using compound fragments for the trans-sialidase of Trypanosoma cruzi: screening for novel inhibitor scaffolds”, J. Mol. Graph. Model., 2013, 45, 84-97.
[cited by applicant]
Mittur, A. “Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders”, Curr. Drug Ther., 2011, 6, 17-34.
[cited by applicant]
Moradi-Afrapoli, F. et al. “In vitro α-glucosidase inhibitory activity of phenolicconstituents from aerial parts of Polygonum hyrcanicum”, Daru Journal of Pharmaceutical Sciences, 2012, 20(1), 37, 6 pages.
[cited by applicant]
Motiwala, H. F. et al. “Remodeling and Enhancing Schmidt Reaction Pathways in Hexafluoroisopropanol”, J. Org. Chem., 2016, 81(8), 1593-1609.
[cited by applicant]
Nandi, A. et al. “Global Identification of O—GlcNAc-Modified Proteins”, Anal. Chem., 2006, 78, 452-458.
[cited by applicant]
Nelson, P. T. et al. “Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature”, J. Neuropathol. Exp. Neurol., 2012, 71(5), 362-381.
[cited by applicant]
Nettekoven, M. et al. “Synthetic Access to 2-Amido-5-aryl-8-methoxy-triazolopyridine and 2-Amido-5-morpholino-8-methoxy-triazolopyridine Derivatives as Potential Inhibitors of the Adenosine Receptor Subtypes”, Synthesis…
[cited by applicant]
Obach, R. S. “Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: and examination of in vitro half-life approach and nonspecific binding to microsomes”, Drug. Metab. Disp…
[cited by applicant]
Okamura, H. et al. “Rhodium-Catalyzed Imination of Sulfoxides and Sulfides: Efficient Preparation of N-Unsubstituted Sulfoximines and Sulfilimines”, Org. Lett., 2004, 6, 1305-1307.
[cited by applicant]
O'Mahony, G. E. et al. “Synthesis of enantioenriched sulfoxides”, Arkivoc, 2011, 1-110.
[cited by applicant]
Orain, D. et al. “Synthesis of Orthogonally Protected 2,6-Diazaspiro[3.5]nonane and 2,6-Diazaspiro[3.4]octane Analogues as Versatile Building Blocks in Medicinal Chemistry”, Synlett, 2015, 26(13), 1815-1818.
[cited by applicant]
Papillon, J. P. N. et al. “Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects”, J. Med. Chem…
[cited by applicant]
Park, M.-J. et al. “High Glucose-induced O—GlcNAcylated Carbohydrate Response Element-binding Protein (ChREBP) Mediates Mesangial Cell Lipogenesis and Fibrosis”, J. Biol. Chem., 2014, 289, 13519-13530.
[cited by applicant]
Pearce, H. L. et al. “Failure Modes in Anticancer Drug Discovery and Development”, Cancer Drug Design and Discovery. Neidle, ed. Boston: Elsevier. (2008):424-435.
[cited by applicant]
Reddy, K. R. et al. “Synthesis of Chiral Benzimidazole-Pyrrolidine Derivatives and their Application in Organocatalytic Aldol and Michael Addition Reactions”, Synth. Commun., 2007, 37(24), 4289-4299.
[cited by applicant]
Rouhi, A. M. et al. “The Right Stuff: From Research and Development to the Clinic, Getting Drug Crystals Right is Full of Pitfalls”, Chem. Eng. News., 2003, 32-35.
[cited by applicant]
Ryan, P. et al. “O—GlcNAc Modification Protects against Protein Misfolding And Aggregation in Neurodegenerative Disease”, ACS Chem. Neurosci., 2019, 10(5), 2209-2221.
[cited by applicant]
Santacruz, K. et al. “Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function”, Science, 2005, 309, 476-481.
[cited by applicant]
Serajuddin, A. T. M. “Salt Formation to Improve Drug Solubility”, Adv. Drug Deliv. Rev., 2007, 59(7), 603-616.
[cited by applicant]
Shan, X. et al. “Reduced protein O-glycosylation in the nervous system of the mutant SOD1 transgenic mouse model of amyotrophic lateral sclerosis”, Neurosci. Lett., 2012, 516, 296-301.
[cited by applicant]
Shen, Q. et al. “Hydroxycoumarin Derivatives: Novel and Potent α-Glucosidase Inhibitors”, J. Med. Chem., 2010, 53(23), 8252-8259.
[cited by applicant]
Shirude, P. et al. “Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents”, J. Med. Chem., 2014, 57(13), 5728-5737.
[cited by applicant]
Silverman, R. B. “Prodrugs and Drug Delivery Systems”, The Organic Chemistry of Drug Design and Drug Action. Academic Press, Inc., 2004, Chapter 8, 352-401.
[cited by applicant]
Simone, J. V. “Introduction”, Cecil Textbook of Medicine. 20th Ed., vol. I . J. Claude Bennet and F. Plum (Eds.) W.B. Sauders Co., 1997, 1004-1010.
[cited by applicant]
Sippy, K. B. et al. “Preparation and characterization of N-(3-pyridinyl) spirocyclic diamines as ligands for nicotinic acetylcholine receptors”, Bioorganic & Med. Chemistry Letters, 2009, 19(6), 1682-1685.
[cited by applicant]
Skedelj, V. et al. “Discovery of the first inhibitors of bacterial enzyme D-aspartate ligase from Enterococcus faecium (Aslfm)”, Eur. J. Med. Chem., 2013, 67, 208-220.
[cited by applicant]
Smith, P. W. et al. “New spiropiperidines as potent and selective non-peptide tachykinin NK2 receptor antagonists”, J. Med. Chem., 1995, 38, 3772-3779.
[cited by applicant]
Song, S. et al. “Efficient and Practical Oxidative Bromination and Iodination of Arenes and Heteroarenes with DMSO and Hydrogen Halide: A Mild Protocol for Late-Stage Functionalization”, Org. Lett., 2015, 17(12), 2886-2…
[cited by applicant]
Sperling, R. A. et al. “Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging—Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's dis…
[cited by applicant]
Spillantini, M. G. et al. “Tau pathology and neurodegeneration”, Lancet Neurol., 2013, 12, 609-622.
[cited by applicant]
Tamura, B. K. et al. “Weight Loss in Patients with Alzheimer's Disease”, J. Nutr. Elder., 2008, 26(3-4), 21-38.
[cited by applicant]
Tan, H. et al. “Rational Screening Approach for Classical Chiral Resolution under Thermodynamic Equilibrium: A Case Study of Diphenyl-Substituted N-Methyl-Piperazine”, Org. Process Res. Dev., 2011, 15(1), 53-63.
[cited by applicant]
Tanuwidjaja, J. et al. “One-Pot Asymmetric Synthesis of Either Diastereomer of tert-Butanesulfinyl-protected Amines from Ketones”, J. Org. Chem., 2007, 72, 626-629.
[cited by applicant]
The Merck Manual, “Acute Leukemia”, (Online Edition), 2013, 6 pages.
[cited by applicant]
The U. S. Pharmacopeia 38—National Formulary 35 Chapter 941, Characterization of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD) Official May 1, 2015, 427-431.
[cited by applicant]
Thiel, O. R. et al. “Practical Synthesis of a Vanilloid Receptor-1 Antagonist”, J. Org. Chem., 2008, 73(9), 3508-3515.
[cited by applicant]
Trapannone, R. et al. “O—GlcNAc transferase inhibitors: current tools and future challenges”, Biochem. Soc. Trans., 2016, 44(1), 88-93.
[cited by applicant]
Vasudevan, A. et al. “Identification of aminopiperidine benzamides as MCHr1 antagonists”, Bioorganic & Medicinal Chemistry Letters, 2005, 15(14), 3412-3416.
[cited by applicant]
Volpe, D. A. “Application of Method Suitability for Drug Permeability Classification”, The AAPS Journal, 2010, 12(4), 670-678.
[cited by applicant]
Wall, G. M. “Pharmaceutical Applications of Drug Crystal Studies”, Pharm. Manuf., 1986, 3, 32-42.
[cited by applicant]
Wang, Z. et al. “Enrichment and Site Mapping of O-Linked N-Acetylglucosamine by a Combination of Chemical/Enzymatic Tagging, Photochemical Cleavage, and Electron Transfer Dissociation Mass Spectrometry”, Mol. Cell Prote…
[cited by applicant]
Waterman, K. C. “Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid Dosage Forms”, Pharm. Res., 2007, 24(4), 780-790.
[cited by applicant]
Weinberg, K. et al. “Synthesis and differential functionalisation of pyrrolidine and piperidine based spirodiamine scaffolds”, Tetrahedron, 2013, 69(23), 4694-4707.
[cited by applicant]
Wermuth, C. G. et al. “Designing Prodrugs and Bioprecursors I: Carrier Prodrugs”, The Practice of Medicinal Chemistry: Chapter 31, Academic Press, 1996, 671-696.
[cited by applicant]
Wiessner et al. “A novel non-carbohydrate o-linked beta-n-acetylglucosaminidase inhibitor increases tau o-glcnacylation In vivo”, Abstracts of the Annual Meeting of the Society for Neuroscience, Society for Neuroscience…
[cited by applicant]
Williams, D. R. et al. “Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome”, Brain, 2007, 130, 1566-1576.
[cited by applicant]
Xu, D. et al. “The synthesis of chiral tridentate ligands from I-proline and their application in the copper(II)-catalyzed enantioselective Henry reaction”, Tetrahedron Asymmetry, 2017, 28(7), 954-963.
[cited by applicant]
Yoshida, M. et al. “Study of biodegradable copoly(L-lactic acid/glycolic acid) formulations with controlled release of Z-100 for application in radiation therapy”, Int. J. Pharm., 1995, 115, 61-67.
[cited by applicant]
Youngdale, G. A. et al. “Synthesis and pharmacological activity of 3-(2-pyrrolidinyl)indoles”, J. Med. Chem., 1964, 7, 415-427.
[cited by applicant]
Yu, Y. J. et al. “One-Pot Synthesis of Spirocyclic or Fused Pyrazoles from Cyclic Ketones: Calcium Carbide as the Carbon Source in Ring Expansion”, Org. Chem. 2017, 82(18), 9479-9486.
[cited by applicant]
Yuzwa, S. A. et al. “O—GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond”, Chem. Soc. Rev., 2014, 43, 6839-6858.
[cited by applicant]
Yuzwa, S. A. et al. “A potent mechanism-inspired O—GlcNAcase inhibitor that blocks phosphorylation of tau in vivo”, Nat. Chem. Biol., 2008, 4(8), 483-490.
[cited by applicant]
Yuzwa, S. A. et al. “Increasing O—GlcNAc slows neurodegeneration and stabilizes tau against aggregation”, Nat. Chem. Biol., 2012, 8(4), 393-399.
[cited by applicant]
Yuzwa, S. A. et al. “Mapping O—GlcNAc modification sites on tau and generation of a site-specific O—GlcNAc tau antibody”, Amino Acids, 2011, 40, 857-868.
[cited by applicant]
Zenzola, M. et al. “Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides”, Angew. Chem. Int. Ed., 2016, 55, 7203-7207.
[cited by applicant]
Zhang, C. et al. “Nontraditional Reactions of Azomethine Ylides: Decarboxylative Three-Component Couplings of α-Amino Acids”, J. Am. Chem. Soc., 2010, 132(6), 2, 1798-1799.
[cited by applicant]
U.S. Appl. No. 18/913,906, filed Oct. 11, 2024 by Quattropani et al.
[cited by applicant]
U.S. Appl. No. 18/957,245, filed Nov. 22, 2024, by Quattropani et al.
[cited by applicant]
U.S. Appl. No. 18/957,291, filed Nov. 22, 2024, by Quattropani et al.
[cited by applicant]
CAS Registry Entry: 890335-15-6 (STN data summary sheet). Entered STN: Jul. 3, 2006, 1 pg.
[cited by applicant]
Addis et al. “Efficient Conversion of Astrocytes to Functional Midbrain Dopaminergic Neurons Using a Single Polycistronic Vector”, (2011) PLoS One: e28719 (8 pages).
[cited by applicant]
Alenghat T. et al. “Histone deacetylase 3 coordinates commensal bacteria-dependent intestinal homeostasis”, (2013) Nature 504:153-157.
[cited by applicant]
Boxer et al. “Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial”, Lancet Neurol. 2014;13(7):676-85.
[cited by applicant]
Boxer et al., “Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches”, Lancet 16:552-563, 2017.
[cited by applicant]
Chen et al. “Protective Effects of Glucosamine on Oxidative-Stress and Ischemia/Reperfusion-Induced Retinal Injury”, (2015), Invest Ophthalmol. Vis Sci. 56(3):1506-1516.
[cited by applicant]
Co-pending U.S. Appl. No. 18/570,861, inventors Beher; Dirk et al., filed on Dec. 15, 2023.
[cited by applicant]
Fleming et al. “Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human alpha-Synuclein”, 2004, The Journal of Neuroscience, 24 (42):9434-40.
[cited by applicant]
Gilbert S. et al. “Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation”, (2012) EMBO Mol. Med.4: 109-124.
[cited by applicant]
Han et al. “Direct Reprogramming of Fibroblasts into Neural Stem Cells by Defined Factors”, (2012) Cell Stem Cell 10: 465-472.
[cited by applicant]
Hinz et al., “Molecular Genetics of Neurodegenerative Dementias”, Cold Spring Harbor Perspectives in Biology, 2017, 9:a023705 (23 pages).
[cited by applicant]
Höglinger et al., “Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy”, Nature Genetics 43 :699-705, 2011.
[cited by applicant]
Höglinger et al. (2017) “Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials”, Movement Disorders, 32(6):842-852.
[cited by applicant]
Höglinger et al. (2017) “Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria”, Movement Disorders, 32:853-64.
[cited by applicant]
Kim J. et al. “Direct reprogramming of mouse fibroblasts to neural progenitors”, (2011) Proc Natl Acad Sci USA 108(19):7838-7843.
[cited by applicant]
Kuhn J. et al. “Deep Brain Stimulation of the Nucleus Basalis of Meynert in Early Stage of Alzheimer's Dementia”, (2015) Brain Stimulation 8:838-839.
[cited by applicant]
Levine et al.(2019) “α-Synuclein O—GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease”, Proc. Natl. Acad. Sci. USA 116(5):1511-1519.
[cited by applicant]
Lim et al. “Generation of Dopamine Neurons from Rodent Fibroblasts through the Expandable Neural Precursor Cell Stage”, (2015) J. Biol. Chem. 290:17401-17414.
[cited by applicant]
Lozano et al. (2016) “A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's Disease”, Journal of Alzheimer's Disease, 54 :777-787.
[cited by applicant]
Lujan E. et al. “Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells”, (2012) Proc Natl Acad Sci USA 109 :2527-2532.
[cited by applicant]
Matsui T. et al. “Neural Stem Cells Directly Differentiated from Partially Reprogrammed Fibroblasts Rapidly Acquire Gliogenic Competency”, (2012) Stem Cells 30: 1109-1119.
[cited by applicant]
Mayer, P. “On the Staining of Mucus”, (1897), Mitt. Zool. Stn. Neape., 12, p. 303-330.
[cited by applicant]
Mirzadeh Z. et al. “The rationale for deep brain stimulation in Alzheimer's disease”, (2016) J. Neural Transm (Vienna) 123: 775-783.
[cited by applicant]
Opposition Arguments, Notice of Opposition, Indian Pharmaceutical Alliance, in Patent Application No. 202127010343 dated Nov. 3, 2021 filed by Asceneuron S.A. (Applicant), dated Feb. 6, 2024, 26 pages.
[cited by applicant]
Paul S. et al. “Evaluation of a PET Radioligand to Image O—GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse”, J. Nucl. Med. 2019, 60(1), 129-134.
[cited by applicant]
Racine R.J. “Modification of Seizure Activity by Electrical Stimulation: I. After-Discharge Threshold”, Electroencephalography and Clinical Neurophysiology 32(3), 269-279 (1972).
[cited by applicant]
Rockenstein E, et al. “Differential Neuropathological Alterations in Transgenic Mice Expressing alpha-synuclein From The Platelet-derived Growth Factor and Thy-1 Promoters”, Journal of Neuroscience Research 68:568-578 (…
[cited by applicant]
Sanchez et al. “Human and rodent temporal lobe epilepsy is characterized by changes in OGlcNAc homeostasis that can be reversed to dampen epileptiform activity”, (2019) Neurobiology of Disease 124: 531-543.
[cited by applicant]
Sankar T et al. “Deep Brain Stimulation Influences Brain Structure in Alzheimer's Disease”, (2015) Brain Stimulation 8:645-654.
[cited by applicant]
Sheng C. et al. “Direct reprogramming of Sertoli cells into multipotent neural stem cells by defined factors” (2012) Cell Res 22: 208-218.
[cited by applicant]
Stamelou M et al. (2016) “Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy”, Mov Disord. 31 (5):742-747.
[cited by applicant]
Tolosa et al. (2014) “A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy”, Movement Disorders 29(4):470-478.
[cited by applicant]
Vierbuchen T. et al. “Direct conversion of fibroblasts to functional neurons by defined factors”, (2010) Nature 463:1035-1041.
[cited by applicant]
Wahlund et al. (2001) “A new rating scale for age-related white matter changes applicable to MRI and CT”, Stroke, 32(6):1318-1322.
[cited by applicant]
Zhang S. Z. et al. “Modeling Neurological Disease by Rapid Conversion of Human Urine Cells into Functional Neurons”, (2016) Stem Cells International, 2016: 2452985 (9 pages).
[cited by applicant]
Zhao J. et al. “Neuronal Transcription Factors Induce Conversion of Human Glioma Cells to Neurons and Inhibit Tumorigenesis”, (2012) PLoS ONE7:5e41506 (11 pages).
[cited by applicant]
Zhao M, et al. “Deficiency in intestinal epithelial O—GlcNAcylation predisposes to gut inflammation”, (2018) EMBO Mol. Med. 10: e8736 (18 pages).
[cited by applicant]
Katritzky et al., “Tautomerism in drug discovery”. Journal of Computer-aided Molecular Design. (Jun. 2010); 24: 475-84.
[cited by applicant]
Kharkevich “Pharmacology”, 2010, pp. 73-74, 10th ed. M.: GEOTAR-Media.
[cited by applicant]
Mashkovsky “Medicinal Drugs”, 2001, p. 11, vol. 1, 14th Ed., S.B. Divov, Moscow, 2 pages.
[cited by applicant]
Office Action issued in Russian Application No. 2024100814/04(001517), mailed Nov. 29, 2024, with English translation, 26 pages.
[cited by applicant]
Pokrovsky “The Small Medical Encyclopedia”. 1992, vol. 3, pp. 100-103. The Comprehensive Russian Encyclopedia.
[cited by applicant]
Zhulenko “Pharmacology”, 2008, pp. 34-35, M.: Koloss, in non-English, Russian only.
[cited by applicant]